TFX vs. STE, PODD, BAX, HOLX, GMED, MASI, ITGR, ATRC, IART, and ATEC
Should you be buying Teleflex stock or one of its competitors? The main competitors of Teleflex include STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), Masimo (MASI), Integer (ITGR), AtriCure (ATRC), Integra LifeSciences (IART), and Alphatec (ATEC). These companies are all part of the "health care equipment" industry.
Teleflex vs.
Teleflex (NYSE:TFX) and STERIS (NYSE:STE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
Teleflex has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
STERIS has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
In the previous week, STERIS had 3 more articles in the media than Teleflex. MarketBeat recorded 14 mentions for STERIS and 11 mentions for Teleflex. STERIS's average media sentiment score of 1.40 beat Teleflex's score of 0.61 indicating that STERIS is being referred to more favorably in the news media.
Teleflex received 187 more outperform votes than STERIS when rated by MarketBeat users. However, 59.19% of users gave STERIS an outperform vote while only 59.19% of users gave Teleflex an outperform vote.
95.6% of Teleflex shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 1.4% of Teleflex shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
STERIS has a net margin of 8.66% compared to Teleflex's net margin of 7.85%. Teleflex's return on equity of 14.19% beat STERIS's return on equity.
Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.8%. STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 1.0%. Teleflex pays out 27.0% of its earnings in the form of a dividend. STERIS pays out 48.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has raised its dividend for 20 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Teleflex currently has a consensus target price of $252.50, indicating a potential upside of 44.95%. STERIS has a consensus target price of $258.75, indicating a potential upside of 18.23%. Given Teleflex's higher possible upside, equities analysts plainly believe Teleflex is more favorable than STERIS.
Summary
STERIS beats Teleflex on 12 of the 20 factors compared between the two stocks.
Get Teleflex News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teleflex Competitors List
Related Companies and Tools
This page (NYSE:TFX) was last updated on 2/22/2025 by MarketBeat.com Staff
